Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial

Published:2019-05 Issue:5 Volume:20 Page:649-662
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Davies Andrew,Cummin Thomas E,Barrans Sharon,Maishman Tom,Mamot Christoph,Novak Urban,Caddy Josh,Stanton Louise,Kazmi-Stokes Shamim,McMillan Andrew,Fields Paul,Pocock Christopher,Collins Graham P,Stephens Richard,Cucco Francesco,Clipson Alexandra,Sha Chulin,Tooze Reuben,Care Matthew A,Griffiths Gareth,Du Ming-Qing,Westhead David R,Burton Catherine,Johnson Peter W M

Funder

Janssen-Cilag and endorsed by Cancer Research UK

Precision Medicine for Aggressive Lymphoma consortium

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma;Coiffier;N Engl J Med,2002

2. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles;Cunningham;Lancet,2013

3. Impact of age and socioeconomic status on treatment and survival from aggressive lymphoma: a UK population-based study of diffuse large B-cell lymphoma;Smith;Cancer Epidemiol,2015

4. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study;van Imhoff;J Clin Oncol,2016

5. Stromal gene signatures in large-B-cell lymphomas;Lenz;N Engl J Med,2008

Cited by 207 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma;Blood Cancer Journal;2024-09-12

2. A Real‐World Data‐Based Analysis of Prognostic Indices as Part of Trial Eligibility Criteria in Diffuse Large B‐Cell Lymphoma Patients;European Journal of Haematology;2024-09-10

3. The impact of trial inclusion criteria on outcomes in DLBCL patients treated with R-CHOP in the first line: a Danish nationwide study;Leukemia & Lymphoma;2024-09-03

4. Genomics in Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2024-09

5. Evaluating the impact of laboratory-based eligibility criteria by race/ethnicity in first-line clinical trials of DLBCL;Blood Advances;2024-08-16